levodopa/carbidopa oral formulation A
Outer sachet 100mg CD/100mg LD and inner sachet 0mg CD /300mg LD
Loading study record…
Loading study record…
Achieving sustained blood levels of carbidopa/levodopa has been a challenge in the treatment of PD and although levodopa remains the most commonly used drug, motor fluctuations remain a major disability especially in advanced Parkinson's disease. The aim of this study is to determine the efficacy of a novel oral carbidopa-levodopa formulation in achieving a sustained blood level of levodopa and carbidopa in normal volunteers.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2026-06-25
What this record can show
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Interventions
Outer sachet 100mg CD/100mg LD and inner sachet 0mg CD /300mg LD
Outer sachet 100mg CD/0mg LD and inner sachet 0mg CD /400mg LD
Eligibility
primary outcomes
Time frame: 4 times, then every 60 mins for a total of 6 hours after administration (total of 9 blood samples)
Carbidopa/levodopa serum level
Publications
No exact PMID-linked public article is currently readable locally.